Non-Hodgkin Lymphoma (Nhl) Therapeutics Market Size to grow by USD 6956.5 million between 2024-2028
According to a research report “ Non-Hodgkin Lymphoma (Nhl) Therapeutics Market” by Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy, Others) Therapy (Immunotherapy, Targeted therapy, Chemotherapy) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 6956.5 million, at a CAGR of 9.45% during the forecast period. The Non-Hodgkin Lymphoma (NHL) therapeutics market presents significant opportunities for innovation, as many approved treatments exist for this type of blood cancer, yet an unmet need persists. Chemotherapy drugs have traditionally dominated the treatment landscape for various types of cancer, including NHL. However, in the NHL therapeutics market, targeted and immunotherapies hold a larger market share. This trend can be attributed to the long-term side effects of chemotherapies, which often result in reduced patient compliance. Consequently, the NHL treatment landscape has shifted towards targeted therapies and immunotherapies. Despite advancements, the pharmacokinetics and pharmacodynamics of treatments for advanced or metastatic lymphomas, such as Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and Follicular Lymphoma (FL), warrant further improvement..
Browse market data tables, figures, and in-depth TOC on “Non-Hodgkin Lymphoma (Nhl) Therapeutics Market” by Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy, Others) Therapy (Immunotherapy, Targeted therapy, Chemotherapy) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By Distribution Channel, the Hospital pharmacy segment is projected to dominate the market size in 2024
The Non-Hodgkin Lymphoma (NHL) therapeutics market represents a significant business opportunity due to the increasing prevalence of this cancer type and the continuous development of innovative treatment options. Key players in this market include Roche, Merck, and Johnson & Johnson, who are investing heavily in research and development to launch effective NHL therapies. These companies are focusing on monoclonal antibodies, targeted therapies, and immunotherapies to address unmet medical needs and improve patient outcomes. The market is expected to grow steadily in the coming years, driven by increasing demand for advanced treatment options and expanding patient populations.
By Therapy, Immunotherapy segment is expected to hold the largest market size for the year 2024
The Non-Hodgkin Lymphoma (NHL) therapeutics market represents a significant business opportunity due to the increasing incidence and prevalence of this disease worldwide. Key players in this market are developing innovative treatments, including targeted therapies and immunotherapies, to address the unmet medical needs of NHL patients and improve their quality of life. The market is expected to grow steadily, driven by advancements in research and development, as well as increasing healthcare expenditures.
North America is forecasted to hold the largest market size by region in 2024
The Non-Hodgkin Lymphoma (NHL) therapeutics market represents a significant business opportunity due to the increasing prevalence of this cancer type and the continuous development of innovative treatments. Key players in this market focus on delivering effective and targeted therapies, including chemotherapies, monoclonal antibodies, and immunotherapies, to improve patient outcomes and meet unmet medical needs. Growing research and development investments, coupled with regulatory approvals, are expected to drive market growth.
The Non-Hodgkin Lymphoma (Nhl) Therapeutics Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
Non-Hodgkin Lymphoma (NHL) is a type of hematologic malignancy that accounts for over 45,000 new cases in the US each year. Healthcare providers and healthcare systems are constantly seeking effective therapeutic options to improve patient outcomes. Intensity-modulated radiation therapy (IMRT) and localized lymphomas have shown promising results in managing early-stage NHL. IMRT allows for precise delivery of radiation, minimizing damage to surrounding healthy tissue. Recent advances in NHL therapeutics include targeted therapies and immunotherapy. Axicabtagene ciloleucel and Lisocabtagene maraleucel are two FDA-approved NHL drugs that utilize chimeric antigen receptor (CAR) T-cell therapy. The Oncology Journal recently published data on the uExcel Technology Platform and uAIFI Technology Platform, which utilize artificial intelligence to optimize radiation therapy (RT) planning and delivery in NHL treatment. RT, chemotherapy, and targeted therapies continue to be essential components of NHL treatment. The combination of these modalities can lead to improved patient outcomes. As the NHL therapeutics market continues to evolve, healthcare providers and healthcare systems must stay informed to provide the best possible care for their patients.
Market Research Overview
Non-Hodgkin Lymphoma (NHL) is a type of hematologic malignancy that affects B and T cells. The NHL therapeutics market is witnessing significant growth due to the introduction of innovative treatments like monoclonal antibodies, such as Rituximab, and CAR T-cell therapies, including Axicabtagene ciloleucel and Lisocabtagene maraleucel. These therapies target specific genetic abnormalities and molecular subtypes, such as B-cell lymphomas and T-cell lymphomas. Radiation therapy, including intensity-modulated radiation therapy and proton therapy, remains a crucial part of NHL treatment. Healthcare providers and systems are increasingly adopting advanced technologies like the uExcel Technology Platform and uAIFI Technology Platform to improve diagnosis and personalize treatment plans. NHL drugs like immune checkpoint inhibitors and targeted therapies, such as C-CAR039, are also gaining popularity. Patients can access these therapies through online pharmacies and hospital pharmacies. However, healthcare policies and research institutions collaborating with pharmaceutical companies are essential to ensuring accessibility and affordability. Toxicities associated with NHL treatments, including chemotherapy, are a concern. Precision medicine and molecular subtypes research are crucial in minimizing side effects and improving patient outcomes. Diagnostic techniques, such as genetic mutation analysis and signaling pathway identification, are vital in developing effective NHL therapeutics.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
